HK Stock Market Move | HBM HOLDINGS-B(02142) rose more than 4% after Yingshi, with a forecasted mid-term profit of approximately $62 million to $67 million.

HBM HOLDINGS-B(02142) rose more than 4% following the profit announcement, with a 4.53% increase to HK$12.91 at the time of writing, with a turnover of HK$2.064 million. On the news front, on July 24th, HBM HOLDINGS-B issued a statement forecasting revenue for the six months ending June 30, 2026, to be between approximately $120 million USD (equivalent to about HK$9.41 billion) and approximately $125 million USD (equivalent to about HK$9.8 billion), compared to around $101 million USD for the same period ending June 30, 2025. Expected net profit for the six months ending June 30, 2026, is projected to be between approximately $62 million USD (equivalent to about HK$4.86 billion) and approximately $67 million USD (equivalent to about HK$5.25 billion). Expected adjusted net profit total is estimated to be between $70 million USD (equivalent to about HK$5.49 billion) and $75 million USD (equivalent to about HK$5.88 billion). The announcement stated that the expected revenue growth and scalable profits are mainly attributed to: continued strategic partnerships with leading global pharmaceutical companies, such as long-term strategic partnerships with AstraZeneca and global strategic partnerships with Pfizer; innovative products for external licensing and collaboration, such as the licensing agreement reached with Solstice Oncology and milestone payments triggered by the progress of past external licensing projects; strong growth in non-biological antibody-related businesses, including income generated from antibody transactions and antibody discoveries, such as collaboration with Longsha.